'I remember standing with Bob Horvitz at the window of the old lecture room a year or so after we moved to Hinxton, looking at the enormous hole in the ground that was to be our new building. "John," he asked me, "do you really know what you are doing?"' Thus Sulston recalls one moment in the huge shift from being a researcher on the genetics and development of the worm Caenorhabditis elegans at the MRC Laboratory of Molecular Biology in Cambridge to director of one of the biggest gene sequencing labs in the world. 'Some of my oldest colleagues and friends could not hide their astonishment that I should have ended up in this position,' he writes. Britain was set to be a major player in the goal of sequencing the human genome with funding from the Wellcome trust and Sulston was to be in charge. His book*, written with author Georgina Ferry, gives his account of this extraordinary project.
Sulston looks to the first musing about such an audacious project. In 1984, molecular biologist Robert Sinsheimer at the University of California at Santa Cruz, began to wonder why the large sums of money involved in major telescope projects should not be raised for biology. He wondered if there were scientific opportunities that were being overlooked, simply because we were not thinking on an adequate scale.
Sinsheimer thought about developing a genome sequencing institute at Santa Cruz and convened a meeting of around a dozen scientists with expertise in DNA mapping, automated sequencing or data management. Sulston was there, together with LMB colleague Bart Barrell standing in for Sydney Brenner. 'The mood swung from extreme scepticism to confidence it could be done but should it be done? There was a lot of suspicion of the 'big science' approach. But overall the conclusion was positive.' 'I felt amazed that we were all sitting discussing making an attack on the human genome.' But Sulston had no idea any such plans would affect his work on the worm.
Sinsheimer didn't get his institute because of internal politics at the University of California but the idea had been sown and advocates like Walter Gilbert of Harvard University were dubbing it the grail of human genetics. By June 1986 the ideas were being discussed at a Cold Spring Harbor meeting on human genetics, but Gilbert's estimate that the project could cost $3 billion caused uproar with many listeners assuming that funds for biological research would diverted to it.
But the US Congress had now seized on the idea so the momentum for a structure-based approach to the genome was unstoppable.
The But a much bigger change in his life than starting sequencing was the business of taking on new people. 'I had never supervised more than one technician before, and hadn't made a very good job of that. It took me a while to realize that going into sequencing was going to lead to a big management structure,' he says. But, in spite of early concerns by his friends and colleagues, he succeeded.
By 1993 the collaboration on the worm was not only the most productive genome sequencing operation in the world, but the biggest. 'But as we began to establish our reputation, the first signs had appeared of a belief that private enterprise could do as well or better than the public project, and could do it quicker and more cheaply'.
Emboldened by their own success, Sulston sought to rampup funding to speed-up sequencing but found the agencies jittery. They had already committed substantial sums and cheaper and faster technologies might be developed. `It's their one failure of nerve,' Sulston now believes -no new technologies were forthcoming, just incremental improvements -and new funds might have helped stall the private challenge to the HGP which came as a bombshell early in May 1998.
Word had got out that Craig Venter, who had left the NIH in 1992 to found the Institute for Genome Research (TIGR), had got industrial backing to sequence the human genome which he aimed to complete in three years. Frantic phone calls and emails followed between the HGP players. Michael Morgan, programme director at the Wellcome Trust, was called by Jim Watson in a taxi crossing London. 'What are we going to do?' he asked. Sulston recounts the serious worries that the news brought, the US reaction of cautious welcome and his own deep concerns about the prospect of a privatized genome. A major eye-opener for Sulston was the power of public relations. Venter had given his story to the New York Times which ran it on May 10, the day before his press conference, where he announced that it might be better if the HGP left the human sequence to him and they turn their attention to the laboratory mouse.
Many stories ran that Celera, the new company, could carry out the project more cheaply and more quickly than the HGP which met with great interest amongst politicians in the US scrutinizing federal spending and value for money. 'The penetrative power of Celera's PR had so convinced the newspapers, and through them everyone, including many of my fellow scientists, that my own truths counted for nothing… The only recourse is to compete on the PR front in the first place. I found that a profoundly depressing thought.' But the Wellcome Trust came up with a feisty response and gave Sulston a big boost in funds. 'We have to do this,' the governors said, when they realised public access to the genome might be at stake. The news also bolstered the NIH which increased Waterston's funding. The HGP was fighting.
The story describes the raw politics that saw simultaneous publication of two draft sequences in different journals last year. Sulston's uncompromising stand on a public genome certainly caused some difficulties for his colleagues but his book champions its virtues. Historians will find much of interest, as will anyone else with an interest in modern biology. It's a riveting read.
Magazine R231
Genome legacy: the Sanger Centre at the Wellcome Trust genome campus in Hinxton, near Cambridge, that has made a major contribution to the human genome sequence.
